TY - JOUR
T1 - Clinical and Socioeconomic Burden of RSV Infections Among Older Adults in Primary Care
T2 - An International Prospective Cohort Study
AU - Hak, Sarah F
AU - Wildenbeest, Joanne G
AU - Bracaloni, Sara
AU - Scarpaci, Michela
AU - Cosci, Tommaso
AU - Esposito, Enrica
AU - Chironna, Maria
AU - Panatto, Donatella
AU - Icardi, Giancarlo
AU - Torrisi, Melissa
AU - Bonaldo, Leonardo
AU - Mammolenti, Eugenio
AU - te Bogt, Emma
AU - Vlaskamp-Smit, Jacqueline
AU - Bont, Louis J
AU - Rizzo, Caterina
AU - Venekamp, Roderick P
N1 - © 2025 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
PY - 2025/10
Y1 - 2025/10
N2 - Introduction: Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of acute respiratory infections (ARI) in older adults. However, primary care data on RSV infections are scarce. Methods: We conducted a prospective cohort study over two winter seasons (2022–2023 and 2023–2024) in Italy and the Netherlands (NCT06318936). Older adults (≥ 60 years) presenting to primary care with ARI were tested for RSV and influenza. Clinical and socioeconomic burden was assessed through questionnaires on Days 1, 14, and 30. In secondary analyses, we compared between RSV- and influenza-positive patients and estimated RSV-ARI incidence in Dutch primary care. Results: Of 703 older adults tested, 93 (13.2%) were RSV-positive and 100 (14.2%) influenza-positive. In RSV patients (mean age: 76 years [SD: 8], 63% ≥ 1 comorbidity), mean illness duration was 17 days (SD: 10). Repeat primary care visits occurred in 38% (33/87), emergency department referral in 5% (4/88), and hospitalization in 2% (2/88) of RSV patients. The mean costs per RSV episode were €78.1 (95%CI: 74.4–81.8) and €279.7 (95%CI: 245.5–318.2) from a healthcare system and societal perspective, respectively. The annual RSV-ARI incidence rate was 10.3 episodes per 1000 person-years. RSV patients were significantly older, and had less often fever, muscle pain, and fatigue than influenza patients, but clinical and socioeconomic burdens were comparable. Conclusions: This prospective study is the first sufficiently large to demonstrate that the primary care burden of RSV infections among older adults is substantial and comparable with influenza. These findings are highly relevant for informing public health decisions on novel RSV vaccines.
AB - Introduction: Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of acute respiratory infections (ARI) in older adults. However, primary care data on RSV infections are scarce. Methods: We conducted a prospective cohort study over two winter seasons (2022–2023 and 2023–2024) in Italy and the Netherlands (NCT06318936). Older adults (≥ 60 years) presenting to primary care with ARI were tested for RSV and influenza. Clinical and socioeconomic burden was assessed through questionnaires on Days 1, 14, and 30. In secondary analyses, we compared between RSV- and influenza-positive patients and estimated RSV-ARI incidence in Dutch primary care. Results: Of 703 older adults tested, 93 (13.2%) were RSV-positive and 100 (14.2%) influenza-positive. In RSV patients (mean age: 76 years [SD: 8], 63% ≥ 1 comorbidity), mean illness duration was 17 days (SD: 10). Repeat primary care visits occurred in 38% (33/87), emergency department referral in 5% (4/88), and hospitalization in 2% (2/88) of RSV patients. The mean costs per RSV episode were €78.1 (95%CI: 74.4–81.8) and €279.7 (95%CI: 245.5–318.2) from a healthcare system and societal perspective, respectively. The annual RSV-ARI incidence rate was 10.3 episodes per 1000 person-years. RSV patients were significantly older, and had less often fever, muscle pain, and fatigue than influenza patients, but clinical and socioeconomic burdens were comparable. Conclusions: This prospective study is the first sufficiently large to demonstrate that the primary care burden of RSV infections among older adults is substantial and comparable with influenza. These findings are highly relevant for informing public health decisions on novel RSV vaccines.
KW - RSV
KW - burden
KW - costs
KW - incidence
KW - older adults
KW - outpatient
KW - primary care
KW - respiratory syncytial virus
KW - Prospective Studies
KW - Humans
KW - Middle Aged
KW - Respiratory Syncytial Virus, Human
KW - Cost of Illness
KW - Male
KW - Incidence
KW - Aged, 80 and over
KW - Female
KW - Hospitalization/statistics & numerical data
KW - Netherlands/epidemiology
KW - Influenza, Human/epidemiology
KW - Primary Health Care/economics
KW - Respiratory Tract Infections/epidemiology
KW - Respiratory Syncytial Virus Infections/epidemiology
KW - Italy/epidemiology
KW - Aged
UR - https://www.scopus.com/pages/publications/105018398364
UR - https://www.mendeley.com/catalogue/3cc72010-afc4-3d0e-9ebc-4ea1140988ae/
U2 - 10.1111/irv.70174
DO - 10.1111/irv.70174
M3 - Article
C2 - 41074665
AN - SCOPUS:105018398364
SN - 1750-2640
VL - 19
JO - Influenza and other Respiratory Viruses
JF - Influenza and other Respiratory Viruses
IS - 10
M1 - e70174
ER -